Drug intelligence / Profile preview

plant extractive compound

Development stage: Preclinical
Lead developer: Uni-President Enterprises
Administration: Oral

Overview

This is a fixed-dose combination of plant extractives comprising red yeast rice, bitter gourd, chlorella, soy protein, and licorice. It has been investigated in a clinical trial for its efficacy in improving total cholesterol, low-density lipoprotein cholesterol, and triglycerides, as well as other components of metabolic syndrome, in adult subjects. The compound aims to provide multifaceted benefits for cardiovascular health and metabolic disorders.

Other names: plant extractivesplant-extractive combination

Targets

PPARG (Peroxisome proliferator-activated receptor gamma)PPARA (Peroxisome proliferator-activated receptor alpha)

Beyond the preview

Go deeper on plant extractive compound.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on plant extractive compound.

Explore the full profile